KRAS G12C inhibitor + anti-EGFR antibody (colorectal)
In colorectal cancer, a KRAS blocker alone barely works because the cell turns EGFR up; adding an EGFR antibody stops that.
Sotorasib + panitumumab (CodeBreaK 300) and adagrasib + cetuximab (KRYSTAL-1) approved; monotherapy ORR ~10% vs ~30-45% in combination.
Pages like this
not linked directly; found by shared links- PersonKevan M. Shokat
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, Colorectal cancer.
- Key paperOstrem and Shokat: the hidden pocket that made KRAS G12C druggable
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK).
- Key paperCodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer
Shares CodeBreaK 300, Sotorasib, KRAS & RAS inhibitors, EGFR.
- TermKRAS mutation subtypes (G12C, G12D, G12V)
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, Colorectal cancer.
- Key paperCodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug
Shares CodeBreaK 300, Adagrasib, Sotorasib, KRAS & RAS inhibitors.
- ProductPanitumumab
Shares CodeBreaK 300, RAS / RAF / MEK / ERK (MAPK), EGFR, Colorectal cancer.
- IdeaCovalent chemistry for the RAS mutations that still have no drug
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, Colorectal cancer.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), Colorectal cancer.